Adam Lenkowsky serves as Executive Vice President and Chief Commercialization Officer at Bristol Myers Squibb (BMS), where he leads the company's global commercialization efforts. In this pivotal role, he oversees the U.S. and International Commercial organizations, Global Medical Affairs, Market Access & Pricing, and Commercial Analytics & Operations. His leadership focuses on accelerating the delivery of innovative medicines to patients worldwide, driving strategic launches, and optimizing commercial performance across BMS's oncology, immunology, cardiovascular, and hematology portfolios. With over 25 years in the biopharmaceutical industry, Lenkowsky brings extensive experience from senior leadership positions at leading companies. Prior to joining BMS in 2021, he spent more than two decades at Pfizer, rising to Group President of Pfizer Innovative Health and President of the Global Innovative Pharma business. Earlier in his career, he held progressive commercial roles at AstraZeneca and Eli Lilly and Company, honing his expertise in market strategy, product launches, and team leadership across therapeutic areas. Lenkowsky's achievements include spearheading blockbuster product launches such as Ibrance and Xeljanz at Pfizer, contributing to billions in annual revenue growth, and fostering high-performing global teams that navigated complex market dynamics. At BMS, he has been instrumental in advancing key franchises like Opdivo and Eliquis, enhancing patient access through innovative pricing strategies, and integrating data-driven insights to fuel sustainable growth. His strategic vision continues to position BMS as a leader in transforming patient outcomes through breakthrough therapies.